Canopy Growth
One of the original Canadian LPs. Formerly backed by Constellation Brands with US expansion through Acreage Holdings.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Canopy Growth earns a Neutral rating, with a 43 composite score and low 2/5 conviction. Fundamentals and regulatory quality jointly provide the strongest pillar contributions at 58 each, while market performance at 15 and editorial activity at 30 constrain the overall assessment. The fundamentals score reflects 9.6% year-over-year revenue growth, a 65.6 market-cap tier subscore, and a 63.2 cash-runway subscore. Regulatory support comes from an 80 jurisdiction posture and an 80 enforcement subscore. Those positives are offset by weak measured liquidity and limited newsroom activity, leaving the shares firmly inside the Neutral band rather than supporting a more constructive stance.
Licensed fundamentals data show revenue expanding 9.6% year over year, but profitability remains materially negative. Gross margin stands near 28%, while operating margin is negative 24.7%. A net loss of approximately $263 million and an EBITDA loss approaching $27 million confirm that sales growth has not translated into bottom-line improvement. The 6.1% cash-burn ratio contributes to the fundamentals score, although the financial condition remains stretched and the loss profile preserves liquidity and solvency risk. Primary regulatory filings show the latest filing dated June 15, 2026. Filing cadence remains a weak component at 25, with four events recorded over 180 days but none during the latest 90-day period. No enforcement hits support the stronger regulatory contribution. Institutional pricing feeds record no volume in the measured input, aligning with the 15 liquidity subscore, while CIN newsroom coverage records no newsroom or brief hits.
The principal forward catalyst rests with fundamentals: sustained revenue growth converting into better operating economics. The existing gross margin offers a base for leverage, but the negative operating margin and EBITDA result require measurable cost absorption before the 58 fundamentals pillar can drive an upgrade. Strong jurisdiction and enforcement scores provide regulatory stability, yet improved filing cadence alone cannot offset weak profitability, market liquidity, and editorial momentum. The single most important signal to watch is a clear narrowing of the operating-margin loss in the next primary regulatory filing.
- Headquarters
- 1 HERSHEY DRIVE, SMITH FALLS, A6, K7A0A8
- Phone
- 855-558-9333
- CEO
- Luc Mo***u
- CFO
- Thomas St***t
- SEC CIK
- 1737927
- Website
- Company website
- Market cap
- $435.5M
- Enterprise value
- $346.8M
- Price to book
- 0.84
- Price to sales
- 1.53
- EV / EBITDA
- 11014.10
- Revenue (TTM)
- $284.6M
- Gross profit (TTM)
- $79.5M
- EBITDA
- $-26.8M
- Operating margin
- -24.7%
- Profit margin
- -92.4%
- Rev growth YoY
- 9.6%
- Return on equity
- -44.7%
- Return on assets
- -3.9%
- EPS (TTM)
- $-0.62
- EPS est. current year
- $-0.47
- Wall St. target price
- $1.23
- Shares outstanding
- 422.2M
- Insider ownership
- 0.2%
- Institutional ownership
- 7.9%
- Beta
- 2.42
- Full-time employees
- 1,128
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEDAR+
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Canopy Growth (CGC)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Canopy Growth (CGC), a cannabis-sector equity listed on NASDAQ in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Analyst average price target $1.58.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown, net loss, insider selling. (3 bullish signals, 4 bearish signals.)
One of the original Canadian LPs. Formerly backed by Constellation Brands with US expansion through Acreage Holdings.
Latest price: $0.93 (-0.50%) on NASDAQ.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CGC are maintained by Cannabis Investor News and refreshed throughout the trading day.